AZD2962, AZD2962
D7770C00001
Phase 2 small_molecule active
Quick answer
AZD2962, AZD2962 for Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Myelodysplastic syndromes, Dysplastic chronic myelomonocytic leukaemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active